Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 6

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 6
---
 rights
are highly uncertain. Any potential pending or future patent applications may not result in patents being issued which protect our technology
or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes
in either the patent laws or interpretation of the patent laws in the United States, the European Union, and other countries may diminish
the value of the underlying patents under our License Agreement or narrow the scope of our patent protection.

Our potential success will depend in large part on
our ability to secure rights to new technologies and obtain and maintain patent protection in the United States, the European Union, and
other major pharmaceutical markets with respect to any new proprietary technology or product candidates.

In addition, the patent prosecution process is expensive
and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or
in a timely manner. We may choose not to seek patent protection for certain innovations and may choose not to pursue patent protection
in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable
or limited in scope. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of
patent applications, or to maintain the patents covering technology under a license agreement. Therefore, these potential patents and
applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Any inability by us or
any future licensor to protect adequately any potential intellectual property we may secure in the future may have a material adverse
effect on our business, operating results, and financial position.

Our Trade Secrets

We also rely upon unpatented trade secrets, and there
is no assurance that others will not independently develop substantially equivalent proprietary information and techniques or otherwise
gain access to our trade secrets or disclose such technology, or that such rights can be meaningfully protected. We require our employees,
consultants, outside scientific collaborators, and other advisers to execute confidentiality agreements upon the commencement of employment
or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual
during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific
circumstances. In the case of our employees, the agreement provides that all inventions conceived by such employees shall be our exclusive
property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our